{"schema_version":"secwatch.filing_event.v1","accession":"0001787306-23-000042","form_type":"8-K","ticker":"ARQT","cik":"0001787306","company_name":"Arcutis Biotherapeutics, Inc.","filed_at":"2023-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.579622+00:00","generated_at":"2026-06-15T09:44:01.477375+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Arcutis Q1 net product revenue $2.8M; net loss $80.1M as ZORYVE launch builds","bullets":["Net product revenue of $2.8M from ZORYVE; unit demand nearly doubled QoQ.","Net loss $80.1M ($1.31/share) vs $64.3M ($1.27) in Q1 2022; SG&A rose to $42.9M.","Cash, equivalents, and marketable securities $333.3M; operating cash burn $80.3M in Q1.","Health Canada approved ZORYVE for plaque psoriasis; launch expected in coming weeks.","FDA accepted NDA for roflumilast foam (seborrheic dermatitis); target action date Dec 16, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001787306-23-000042","json":"https://secwatch.observer/filing/0001787306-23-000042.json","markdown":"https://secwatch.observer/filing/0001787306-23-000042.md","text":"https://secwatch.observer/filing/0001787306-23-000042.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1787306/000178730623000042/0001787306-23-000042-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1787306/000178730623000042/arqt-20230509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T09:44:01.477375+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"296a06650d78ba1c714d56ee5593d083e3d033e2","claim":"Arcutis Biotherapeutics, Inc. reported the quarter ended March 31, 2023 results: revenue $2.8 million.","evidence_excerpt":"by specific reference in such filing. --- EX-99.1 (EX-99.1) --- Arcutis Announces First Quarter 2023 Financial Results and Provides Business Update • Achieved net revenues of $2.8 million for ZORYVE® (roflumilast) cream 0.3% in the first quarter of 2023, with unit demand growth nearly doubling quarter-over-quarter • Continued expansion of commercial payer coverage","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1787306/000178730623000042/0001787306-23-000042-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2023"},{"label":"Revenue","value":"$2.8 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}